A better view

Wearable tech 
Thales Visionix (see case study box) is already developing wearable technology for special forces troops that will help them to identify friend or foe in the middle of a combat battle. Thales is also testing a central AR display that can be used by a controller to track and coordinate firefighting teams inside a building.

Source: imported from this press release.

Digital warriors

Going digital

Connectivity between systems of systems that all depend on the same C4ISR capability is driving a deep-seated digital transformation within modern land forces. Satellite links, more and more drones and robots deployed on an expanding range of missions (ISR, communication relays, electronic warfare, destruction, engineering, logistics, etc.), sensor networks, central data storage and processing… With all these developments, and the central role played by C4ISR, airland combat is already in the process of going digital.
 
Each development raises issues such as data protection in the cloud, cybersecurity of connected object on the battlefield, cyberoffensive capabilities and the relentless march of robotic systems. Tomorrow’s engagements will likely see the deployment of an initial line of remotely operated ground, naval or airborne systems, which will be the first to draw enemy fire. These systems will have varying degrees of autonomy, but humans will nonetheless continue to take the final decision in combat situations.
 
When digital technologies have been fully assimilated into military doctrines, land forces officers will be able to focus on their core tasks of defining and directing tactical or theatre-level manoeuvres in exactly the same way as a combat aircraft pilot, by virtue of the aircraft’s data fusion capabilities, can focus on core air combat tasks. Tomorrow, as connectivity improves (higher data rates, better data security, more interoperability, etc.), combatants and their various levels of command will be able to fight with a virtually complete vision of the battlefield and the actions taken by the different players. This is the promise of the digital transformation.

 

Unlike Fabrice del Dongo, who could see no further than a few hundred metres in the Battle of Waterloo, future soldiers will share a common vision and know their respective positions.

With sensors everywhere, commanders will direct manoeuvres based on a complete, constantly updated picture of the situation, receiving details about which units are still in action and where supplies (munitions, fuel, etc.) or medical support are needed. Combat units will be ready for action much more quickly and effectively than they can be today. Longer term, cloud-based platforms will use Big Data techniques to analyse data from the field, compare it with data from other situations, and provide ultra-personalised decision support to commanders at both tactical and theatre levels.
 
Last but not least, digital technologies play a crucial role in training, with advanced simulation techniques helping personnel to learn how to use their equipment long before they are deployed in the field. In the future, as well as taking part in conventional exercises, combat troops will be stationed at “smart barracks”, where they will be able to prepare for combat, actively and continuously, well before they are sent into action. Once again, victory lies in innovation.

 

This article was written by Philippe Migault  and published in the Innovations magazine #6.

Source: imported from this press release.

Jewel purpose

Hitting the right spot

The ability to harness the NV centre properties hinges on making diamonds in which the nitrogen vacancy lies just beneath the surface of the crystal – essentially because efficient magnetic coupling depends on intimate contact between sensor and sample material. This is an area the team is working on at the moment.

 

“Our aim is to control all the properties of the nitrogen vacancy, including the position inside the diamond and the orientation,” says Debuisschert. “We need to control all of those properties in order to produce devices that can be used for different applications.”

 

One technique for getting the nitrogen atom in just the right spot is known as ion implantation. This involves shining a beam of ions containing nitrogen at the diamond crystal, which is typically 4mm square and just half a millimetre thick. “We can achieve nitrogen implantations a few nanometres below the surface by controlling the amount of energy of the incoming ions,” explains Debuisschert. Another way to trap nitrogen atoms is to add them while the diamond is still being grown. The stones being used by the DIADEMS team are synthetic and they’re grown using a process known as chemical vapour deposition, which uses a high-temperature gas containing carbon to create the diamond. “By adding nitrogen to this gas, we can create a layer of nitrogen at a controlled position below the surface,” says Debuisschert. “This technique is quite new and is something our research activity is focusing on.”

Source: imported from this press release.

ETCS: Signalling Without frontiers

Why is ETCS needed?

Train control – which allows signalling to stop trains – was first introduced more than a century ago. Incompatible national train control standards are now a major barrier to international traffic along Europe’s rail arteries.
• There are currently more than 20 different train control systems in use across Europe.
• Adapting a single locomotive to work on a neighbouring national network can cost more than €2 million.

How does ETCS help?

Trains fitted with ETCS are able to operate freely over suitablyequipped track in any country. Cab signalling is a vital part of ETCS. This makes it possible not only to get rid of conventional signals but also to operate safely at speeds up to 500kmh. In Europe, more than 40,000km of ETCS track is now in operation across 24 countries.

ETCS Level 1
This is the basic version of ETCS and can be easily superimposed over existing national signalling systems. It provides train protection, speed supervision and cab signalling.
 
ETCS Level 2
The benchmark for main line and high-speed signalling projects. Continuous track-to-train radio delivers performance enhancements and means lineside signals are not needed.
 
ETCS Level 3
Currently in development, ETCS Level 3 promises significant capacity gains, further reductions in lineside infrastructure and the potential for train automation.

Source: imported from this press release.

GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer

MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced the appointment of Jennifer Cook as chief executive officer, effective January 2, 2018. Bill Rastetter, who has been acting as interim chief executive officer since August 2017, will continue in his role as chairman of the Board of Directors, focusing on governance of the company. The company also announced the appointment of Catherine Friedman and Min Cui to its Board of Directors.

“Jennifer is an outstanding leader who brings a wealth of experience from the life sciences industry and we are thrilled she is joining GRAIL. She is recognized for her ability to build and lead organizations, with a talent for bringing out the best in people, and for strategic development and commercialization of product portfolios,” said Bill Rastetter. “While I will be stepping back into my role as chairman, I remain highly committed to GRAIL and am confident that under Jennifer’s leadership this talented team will succeed in its goals of delivering early detection products to people globally.”

“I am honored to be joining GRAIL and to work alongside Bill and the other exceptional leaders and employees at the company,” said Jennifer Cook. “GRAIL has made great progress in the two years since its formation. I am excited to join the team as the company moves into a pivotal year when it is poised to start delivering insights from its clinical studies and begin commercialization.”

As chief executive officer, Ms. Cook will serve on GRAIL’s Board. GRAIL has also appointed two additional seasoned executives to its Board of Directors, Catherine Friedman and Min Cui, further broadening the industry experience and operational excellence across the Board. Ms. Cook, Ms. Friedman and Dr. Cui join GRAIL’s existing board of directors: Bill Rastetter, Jeff Huber, Jose Baselga, Brook Byers, Kaye Foster, Richard Klausner and Robert Nelsen.

GRAIL is building its capabilities in Asia to develop tests for the early detection of cancers prevalent in the region. Based on the company’s collaboration with The Chinese University of Hong Kong, the first product will be launched in 2018 and will be a screening test for the early detection of nasopharyngeal cancer. Nasopharyngeal cancer is a type of cancer located near the upper throat and behind the nasal cavity. It has the highest incidence in middle-aged men in Southern China and Southeast Asia. The test will initially be launched in Hong Kong and subsequently other parts of Asia where nasopharyngeal cancer is prevalent.

GRAIL also continues to remain focused on enrolling its two large studies — the Circulating Cell-free Genome Atlas (CCGA) Study and the STRIVE Study. The company anticipates starting to deliver insights from CCGA in 2018.

About Jennifer Cook

Jennifer Cook joins GRAIL from Roche/Genentech where she is currently head of Clinical Operations in Product Development for Roche Pharmaceuticals, managing a clinical trial portfolio of more than 400 trials with 100,000 participants. Before that she was head of Region Europe for Roche Pharmaceuticals, where she was responsible for achieving the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Ms. Cook started her career at Genentech in early-stage research and subsequently held numerous senior management positions at the company covering the full lifecycle of product development and commercialization. Key positions included leading product portfolio management, a U.S. commercial business unit, and market development. In 2016, she was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Ms. Cook holds a BA in human biology and MS in biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.

About Catherine Friedman and Min Cui

Catherine Friedman has been an independent financial consultant serving public and private companies in the life sciences industry since 2006. Previously, Ms. Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including managing director and head of West Coast Healthcare and co-head of the Biotechnology Practice. Ms. Friedman is a member of the Boards of Directors of Altaba (formerly Yahoo!), Innoviva and Radius Health. Ms. Friedman holds a BA in economics from Harvard University and an MBA from the University of Virginia’s Darden School of Business.

Min Cui is the founder and managing director of Decheng Capital. He is a member of the Board of Directors of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, Ketai Medical, Levitas and SINOMED. Prior to founding Decheng Capital, Dr. Cui was an investment partner at Bay City Capital and director of Strategic Investment for the Southern Research Institute. Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. Dr. Cui received his PhD in cancer biology from Stanford University and his BS and MS in molecular biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America.

About GRAIL’s Clinical Research Program

GRAIL is conducting one of the largest clinical study programs ever pursued in genomic medicine in collaboration with leading community and academic medical centers. GRAIL has initiated two large-scale studies to date:

  • The CCGA Study is an observational study that will characterize the landscape of cell-free nucleic acid profiles in at least 7,000 people with cancer and 3,000 people who do not have cancer. Data from CCGA will be used to develop a deeper understanding of tumor biology and to develop models for distinguishing cancer mutations from non-cancer mutations.
  • The STRIVE Study is a longitudinal, prospective, observational cohort study that will evaluate a blood test for the early detection of breast cancer. The study is enrolling 120,000 women at the time of their screening mammogram. The study will also support development of tests for other cancers that affect women.

About GRAIL

GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company’s funding was led by ARCH Venture Partners and includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, Decheng Capital, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. For more information, please visit www.grail.com.

Source: imported from this press release.

GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer

MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced the appointment of Jennifer Cook as chief executive officer, effective January 2, 2018. Bill Rastetter, who has been acting as interim chief executive officer since August 2017, will continue in his role as chairman of the Board of Directors, focusing on governance of the company. The company also announced the appointment of Catherine Friedman and Min Cui to its Board of Directors.

“Jennifer is an outstanding leader who brings a wealth of experience from the life sciences industry and we are thrilled she is joining GRAIL. She is recognized for her ability to build and lead organizations, with a talent for bringing out the best in people, and for strategic development and commercialization of product portfolios,” said Bill Rastetter. “While I will be stepping back into my role as chairman, I remain highly committed to GRAIL and am confident that under Jennifer’s leadership this talented team will succeed in its goals of delivering early detection products to people globally.”

“I am honored to be joining GRAIL and to work alongside Bill and the other exceptional leaders and employees at the company,” said Jennifer Cook. “GRAIL has made great progress in the two years since its formation. I am excited to join the team as the company moves into a pivotal year when it is poised to start delivering insights from its clinical studies and begin commercialization.”

As chief executive officer, Ms. Cook will serve on GRAIL’s Board. GRAIL has also appointed two additional seasoned executives to its Board of Directors, Catherine Friedman and Min Cui, further broadening the industry experience and operational excellence across the Board. Ms. Cook, Ms. Friedman and Dr. Cui join GRAIL’s existing board of directors: Bill Rastetter, Jeff Huber, Jose Baselga, Brook Byers, Kaye Foster, Richard Klausner and Robert Nelsen.

GRAIL is building its capabilities in Asia to develop tests for the early detection of cancers prevalent in the region. Based on the company’s collaboration with The Chinese University of Hong Kong, the first product will be launched in 2018 and will be a screening test for the early detection of nasopharyngeal cancer. Nasopharyngeal cancer is a type of cancer located near the upper throat and behind the nasal cavity. It has the highest incidence in middle-aged men in Southern China and Southeast Asia. The test will initially be launched in Hong Kong and subsequently other parts of Asia where nasopharyngeal cancer is prevalent.

GRAIL also continues to remain focused on enrolling its two large studies — the Circulating Cell-free Genome Atlas (CCGA) Study and the STRIVE Study. The company anticipates starting to deliver insights from CCGA in 2018.

About Jennifer Cook

Jennifer Cook joins GRAIL from Roche/Genentech where she is currently head of Clinical Operations in Product Development for Roche Pharmaceuticals, managing a clinical trial portfolio of more than 400 trials with 100,000 participants. Before that she was head of Region Europe for Roche Pharmaceuticals, where she was responsible for achieving the commercial success of Europe and leading more than 5,500 employees across the 28 countries of the region. Ms. Cook started her career at Genentech in early-stage research and subsequently held numerous senior management positions at the company covering the full lifecycle of product development and commercialization. Key positions included leading product portfolio management, a U.S. commercial business unit, and market development. In 2016, she was recognized for her contributions to the healthcare industry and inspirational leadership when she was named Woman of the Year by the Healthcare Businesswomen’s Association. Ms. Cook holds a BA in human biology and MS in biology from Stanford University, as well as an MBA from the Haas School of Business at University of California, Berkeley.

About Catherine Friedman and Min Cui

Catherine Friedman has been an independent financial consultant serving public and private companies in the life sciences industry since 2006. Previously, Ms. Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including managing director and head of West Coast Healthcare and co-head of the Biotechnology Practice. Ms. Friedman is a member of the Boards of Directors of Altaba (formerly Yahoo!), Innoviva and Radius Health. Ms. Friedman holds a BA in economics from Harvard University and an MBA from the University of Virginia’s Darden School of Business.

Min Cui is the founder and managing director of Decheng Capital. He is a member of the Board of Directors of AccuraGen, Ariagen, ARMO BioSciences, CardioMed, EpimAb Biotherapeutics, GenapSys, GeneMDx, Ketai Medical, Levitas and SINOMED. Prior to founding Decheng Capital, Dr. Cui was an investment partner at Bay City Capital and director of Strategic Investment for the Southern Research Institute. Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. Dr. Cui received his PhD in cancer biology from Stanford University and his BS and MS in molecular biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America.

About GRAIL’s Clinical Research Program

GRAIL is conducting one of the largest clinical study programs ever pursued in genomic medicine in collaboration with leading community and academic medical centers. GRAIL has initiated two large-scale studies to date:

  • The CCGA Study is an observational study that will characterize the landscape of cell-free nucleic acid profiles in at least 7,000 people with cancer and 3,000 people who do not have cancer. Data from CCGA will be used to develop a deeper understanding of tumor biology and to develop models for distinguishing cancer mutations from non-cancer mutations.
  • The STRIVE Study is a longitudinal, prospective, observational cohort study that will evaluate a blood test for the early detection of breast cancer. The study is enrolling 120,000 women at the time of their screening mammogram. The study will also support development of tests for other cancers that affect women.

About GRAIL

GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company’s funding was led by ARCH Venture Partners and includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, Decheng Capital, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. For more information, please visit www.grail.com.

Source: imported from this press release.

Look deeper

Florida police successfully used facial recognition software at Super Bowl XXXV in 2001 to identify potential criminals and terrorists attending the event. Media reports claim that 19 people with minor criminal records were potentially identified by the software. In the post-9/11 world, enforcement agencies and governments have been reluctant to confirm whether and how they are using the technology but anti-terror experts suggest its use is fairly commonplace.

 

Eric Moncet, head of sector, in charge of citizen security business at Thales, says there are two key ways facial recognition technology is being used by law enforcement and anti-terror agencies: for real time detection and post analysis, following a serious crime or terrorist attack.

 

In ‘fluid’ situations like the coordinated terror attacks that we have witnessed across Europe in the last few years, the technology clearly offers numerous benefits. However, there are a number of hurdles that need to be overcome before the technology can be widely rolled out. One lingering issue surrounds privacy. In October 2016, a report produced by a think tank at Georgetown University in the US urged for greater controls around the use of images searchable by law enforcement agencies using facial recognition technology. The report said that agencies, including the FBI, had access to a database of more than 117 million American citizens, many of whom were law-abiding and a disproportionate number were black.
 
Providers of facial recognition solutions have also got to get to grips with a series of technical challenges to make the technology more fool proof, says Professor Tao.
 
“First, the appearance of the face often changes dramatically due to a number of factors, such as variations in pose and illumination,” he explains. “The appearance variations degrade the performance of existing face recognition algorithms. This challenge is particularly serious for large-scale recognition, where intra-personal and interpersonal appearance changes are subtle. Second, the degradation in image quality in many real-world applications lowers the amount of effective information for recognition; therefore, not all face images can be utilised for reliable recognition.” He adds that facial recognition technology developers are close to overcoming the first problem by designing more powerful deep learning models and collecting more data in terms of different facial appearance variations, which makes it all the more important for the industry to find a way to resolve the second issue.

 
 

Source: imported from this press release.

Ambry Names Tom Schoenherr as Chief Commercial Officer

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics Corporation (Ambry), leaders in genetic testing, announced today Tom Schoenherr will serve as Ambry’s new Chief commercial Officer (CCO). Tom’s primary role will be to build upon Ambry’s success in the genetic testing space following the successful acquisition by Konica Minolta.

Tom Schoenherr brings more than 20 years of commercial experience in molecular diagnostics with a solid track-record for building high-growth companies. Mr. Schoenherr previously led Counsyl’s commercial strategy, and was responsible for driving business growth and increasing market share in the very competitive carrier screening space. He also served in similar roles at Quest, Siemens Healthcare and Abbott Diagnostics.

“We are very excited to have Tom on board to lead our commercial team; he brings a great mixture of sales management, leadership and energy,” says Ambry CEO Dr. Aaron Elliott. “In our partnership with Konica Minolta, Ambry is identifying new market opportunities in the pursuit of precision medicine. We believe Tom is the right person to lead that charge.”

As Ambry’s Chief commercial Officer, Mr. Schoenherr will be responsible for the execution of Ambry’s commercial strategy by overseeing all commercial sales, including business development, client services, genetic specialists and marketing. Mr. Schoenherr will build upon Ambry’s reputation for top quality testing and scientific innovation to lead new market expansion both domestic and globally as a part of Ambry’s growth strategy.

Konica Minolta closed its acquisition of Ambry late October with a mission to combine their existing capabilities in medical imaging, including its high-sensitivity tissue testing immunostaining technology (HSTT), with Ambry’s advanced genetic testing to advance precision medicine.

“We look forward to Tom joining the team to build a commercial organization focused on bringing important research and comprehensive testing to patients,” said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta. “We are certain that the combination of our precise medical imaging, along with Ambry’s expertise in genetic testing will enhance patient care and preserve quality of life.”

“I am excited to be a part of this industry-changing global healthcare dynasty, committed to advancing science and developing breakthrough technologies,” says Mr. Schoenherr. “After pioneering carrier screening at Counsyl, I am excited to propel Ambry to the top of the genetic testing industry.”

About Ambry

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Source: imported from this press release.

Ambry Names Tom Schoenherr as Chief Commercial Officer

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics Corporation (Ambry), leaders in genetic testing, announced today Tom Schoenherr will serve as Ambry’s new Chief commercial Officer (CCO). Tom’s primary role will be to build upon Ambry’s success in the genetic testing space following the successful acquisition by Konica Minolta.

Tom Schoenherr brings more than 20 years of commercial experience in molecular diagnostics with a solid track-record for building high-growth companies. Mr. Schoenherr previously led Counsyl’s commercial strategy, and was responsible for driving business growth and increasing market share in the very competitive carrier screening space. He also served in similar roles at Quest, Siemens Healthcare and Abbott Diagnostics.

“We are very excited to have Tom on board to lead our commercial team; he brings a great mixture of sales management, leadership and energy,” says Ambry CEO Dr. Aaron Elliott. “In our partnership with Konica Minolta, Ambry is identifying new market opportunities in the pursuit of precision medicine. We believe Tom is the right person to lead that charge.”

As Ambry’s Chief commercial Officer, Mr. Schoenherr will be responsible for the execution of Ambry’s commercial strategy by overseeing all commercial sales, including business development, client services, genetic specialists and marketing. Mr. Schoenherr will build upon Ambry’s reputation for top quality testing and scientific innovation to lead new market expansion both domestic and globally as a part of Ambry’s growth strategy.

Konica Minolta closed its acquisition of Ambry late October with a mission to combine their existing capabilities in medical imaging, including its high-sensitivity tissue testing immunostaining technology (HSTT), with Ambry’s advanced genetic testing to advance precision medicine.

“We look forward to Tom joining the team to build a commercial organization focused on bringing important research and comprehensive testing to patients,” said Kiyotaka Fujii, President of Global Healthcare, Konica Minolta. “We are certain that the combination of our precise medical imaging, along with Ambry’s expertise in genetic testing will enhance patient care and preserve quality of life.”

“I am excited to be a part of this industry-changing global healthcare dynasty, committed to advancing science and developing breakthrough technologies,” says Mr. Schoenherr. “After pioneering carrier screening at Counsyl, I am excited to propel Ambry to the top of the genetic testing industry.”

About Ambry

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Source: imported from this press release.

Securities America Names Jim Norwood New President of Financial Institutions Division

LA VISTA, Neb.–(BUSINESS WIRE)–Securities America, a wholly owned subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS, LTS PrA), announced today that Jim Norwood is taking the helm of its financial institutions division.

“This position reflects our commitment to the bank and credit union space,” said Gregg Johnson, executive vice president of branch office development and acquisitions at Securities America. “There’s no one better for the position than Jim Norwood. He’s well known and highly respected. He brings nearly three decades of effective leadership in the financial services industry.”

Norwood has spent the bulk of his 30-year career working with banks and credit unions in an executive leadership capacity and played a critical role in building a significant financial institutions division at one of the nation’s largest independent brokerage firms. Most recently, he held the president’s chair at Priority Financial Group (PFG), which joined Securities America’s independent brokerage and advisory platform in October.

“Our team is extremely happy to see Jim join Securities America,” said Mike Prior, PFG’s chief executive officer. “He has a stellar reputation in the bank and credit union space and truly cares about his clients. Securities America just made a strong financial institutions division even better.”

Norwood said he is thrilled to be part of an organization with such a highly engaged executive leadership team.

“Their vision and mine are the same – to continue our development as the nation’s premier financial institutions division,” he said.

The financial institution space is a highly competitive segment of the industry, said Johnson, and Securities America is committed to delivering all the tools and resources its current 139 financial institutions need to excel.

“We’re also looking forward to continued growth,” he said. “Jim will add to the momentum that Securities America has achieved. His experience and knowledge will help expand our value proposition and enhance the overall client experience at both the institution and advisor levels.”

For more about Securities America Financial Institutions Division
For more about Securities America

About Securities America
Securities America, a wholly owned subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS, LTS PrA), is one of the nation’s largest independent advisory and brokerage firm with more than 2,200 independent advisors and nearly $72 billion in client assets.

Securities offered through Securities America, Inc., member FINRA/SIPC. Advisory services offered through PFG Advisors. PFG Advisors and Priority Financial Group are separate entities from Securities America.

Source: imported from this press release.